Excelerate Health Ventures LLC
Excelerate Health Ventures II LP
Follow-ons only: first sale Jan 2021, per Form D (fund age approximates vintage)
- Vintage
- 2021
- Fund size
- $35M to $39.56M (Form D and SEC adviser filing)
- Stages
- Seed, Series A
- Sectors
- Healthtech, Enterprise SaaS
- Regions
- US
01 · Thesis
No thesis found on the firm's website yet.
02 · Initial check
$500K to $2M (stated by the firm)
Stated by the firm (firm-level)
03 · Who to approach
Named on this fund's Form D
- Andrew Schwab, Managing Partner of the Manager of the General Partner of the Issuer
- B. Bahram, Managing Partner of the Manager of the General Partner of the Issuer
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideA fund focused on AI-powered Pharma Tech and tech-enabled pharma services for early-stage companies. Its initial closing was announced in April 2026.
We have created a premier AI-Powered Pharma Tech and Services fund for early-stage companies.
https://exceleratehealth.com/approach/Firm-wideChecks of $500000 to $2000000
initial checks of $500K–$2M
https://exceleratehealth.com/approach/Firm-wideAn earlier healthcare fund that backed capital-efficient healthcare software companies across provider, payer, and pharma markets.
Our earlier funds backed capital-efficient healthcare software companies across provider, payer, and pharma markets.
https://exceleratehealth.com/portfolio/Firm-wideInvests exclusively in Pharma Tech, B2B SaaS and tech-enabled services with capital-efficient models built to scale.
We invest exclusively in Pharma Tech, B2B SaaS and tech-enabled services with capital-efficient models built to scale.
https://exceleratehealth.com/approach/Firm-wideChecks of $500000 to $2000000
initial checks of $500K–$2M
https://exceleratehealth.com/approach/
06 · Sources
Last verified: Oct 28, 2026